Thymosin alpha-1 (Tα-1) has shown clinical benefits in patients whose immune functions are
severely compromised or ineffective. Therefore, this study is attempted to explore whether
Tα-1 could be used as a therapeutic option for the treatment of immune-related adverse events
(irAEs).